GreenBe Pharma
- Company typePrivate
- Founded2022
- HeadquartersElvas, Portugal
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
GreenBe Pharma firmographics
Firmographics- Name
- GreenBe Pharma
- Legal name
- GreenBE Pharma
- Website
- https://greenbepharma.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
GreenBe Pharma industry classification
Industry- Product category
- Medicinal Cannabis APIs / Pharmaceutical Ingredients
- NAICS
- Medicinal and Botanical Manufacturing (325411)
- SIC
- Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Medicinal Plant Farming (Botanical/Pharmaceutical Crops) (AFAGAGAE)
Keywords
Where GreenBe Pharma is headquartered
LocationHeadquarters
- HQ city
- Elvas
- HQ country
- Portugal
- HQ region
- Europe
Offices1 record
Markets served
GreenBe Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Personnel, Infrastructure, Supply Chain, Technology or R&D, Marketing or Sales
Revenue model
- Cannabis Flower Sales (EU-GMP): Sale of high-quality dried cannabis flowers meeting EU-GMP certification requirements. Products include THC-dominant, CBD-dominant, and balanced chemotype varieties. Capacity of up to 50 kg per week of dried flowers or 2,500-4,000 kg per year depending on variety.
- Active Pharmaceutical Ingredients (API): Supply of Active Pharmaceutical Ingredients for clinical trials, observational studies, and contractual research projects. Provided under EuGMP standards.
- Research Services: Support services for research projects including design and implementation of research projects, laboratory personnel training and support, and chemotype supply for research purposes.
- Extract and Purification: Second phase project to process flowers and obtain extracts and purifications of main cannabinoids using licensed technologies.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom production based on customer specifications |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels3 records
GreenBe Pharma product offering
Product offeringCore offering
GreenBe Pharma cultivates medicinal cannabis in a GACP-certified greenhouse in Elvas, Portugal, and processes it in an adjacent EU-GMP facility to produce Active Pharmaceutical Ingredients (dried cannabis flowers with tailored THC, CBD, and CBDV chemotypes) supplied to pharmaceutical companies. The company also offers GMP cultivation and processing services, planned extraction/purification capabilities, and chemotype research services for clinical trials and contractual research projects.
Product overview
GreenBe Pharma is a medicinal cannabis company offering a vertically integrated portfolio of products and services for the pharmaceutical industry. The core offering includes five proprietary cannabis varieties (Variety A Type, Variety B Type, Variety C Type, Variety D Type, and Forbidden Dream) producing EU-GMP certified dried cannabis flowers as Active Pharmaceutical Ingredients. The company provides GACP-compliant cultivation services (10,000 m2 greenhouse facility) and GMP-compliant processing services (1,500 m2 processing unit) capable of producing 2,500-4,000 kg/year of dried flowers. Supporting services include extraction and purification capabilities, chemotype research services for clinical trials and contractual research, and distribution of Segra International tissue culture clones throughout Europe. The company develops 100% tailored solutions aligned to customer specifications for chemotype, terpene profile, and medical application requirements.
Differentiator
Problem solved
Functional benefit
Products and services
- EU-GMP Cannabis Flower (Medicinal Cannabis API) High-quality dried cannabis flowers meeting EU-GMP certification requirements, supplied as Active Pharmaceutical Ingredients to pharmaceutical companies. Offered in tailored chemotypes including THC-dominant (Variety A Type, Forbidden Dream), Sativa-dominant THC with THCV (Variety B Type), balanced THC/CBD (Variety C Type), and CBD-dominant with CBDV (Variety D Type). Used by pharmaceutical manufacturers in medicines for chronic neuropathic pain, oncology support, Parkinson's, Multiple Sclerosis, and chemotherapy tolerance.
- GACP Cultivation Services Good Agricultural and Collection Practice (GACP) compliant cannabis cultivation in a 10,000 m² greenhouse comprising 19 cultivation rooms, 9 flowering rooms (5,000 m²), 9 vegetative phase rooms (2,500 m²), and a 1,000 m² mothers' room. Provides pharmaceutical clients a complete production chain from mother plants through cloning, rooting, vegetative growth, flowering, and harvesting.
- GMP Processing Services European Good Manufacturing Practice (EU-GMP) compliant processing in a 1,500 m² facility located 6 meters from the greenhouse shipping area. Capabilities include mechanical or manual trimming, drying in 4 rooms with independent environmental control, in-house quality control laboratory, bulk packaging (500 g primary batches), and irradiation services. Export capacity up to 50 kg/week or 2,500-4,000 kg/year of dried flowers.
- Extraction and Purification Services Second-phase service to process cannabis flowers and obtain extracts and purifications of main cannabinoids using licensed technologies. Intended to complement dried flower production with concentrated cannabinoid products for pharmaceutical customers.
- Chemotype Research Services Research services supplying GMP-compliant Active Pharmaceutical Ingredients (chemotypes) for biomedical research. Includes research project design and implementation support, laboratory personnel training, and chemotype supply for clinical trials, observational studies, and contractual research projects. Targeted at pharmaceutical companies and research institutions.
- Segra Tissue Culture Cannabis Clone Distribution European distribution of Segra International's proprietary tissue culture cannabis clones. Clones are DNA-fingerprinted, pathogen-tested, and genetically consistent, with uniform growth characteristics and stable cannabinoid and terpene profiles. Provides European licensed cultivators swift access to elite genetics, bypassing international import complexities.
Quantifiable outcome
- Production capacity of 50 kg/week or 2,500-4,000 kg/year of dried flowers
- +2 more outcomes
Companies that use GreenBe Pharma
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles2 records
GreenBe Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
GreenBe Pharma partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Segra InternationalcoreStrategic partnership making GreenBe Pharma the central point of distribution for Segra's proprietary tissue culture cannabis clones throughout Europe. The collaboration enables European cultivators to efficiently access Segra's award-winning tissue culture cannabis clones through a localized European hub, reducing logistics and regulatory complexities associated with international imports. Segra provides DNA fingerprinting, pathogen-tested, genetically consistent clones; GreenBe Pharma provides GACP/GMP compliant facilities and local distribution.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
GreenBe Pharma competitors and assessment
Company assessmentBroad incumbents
- Canopy Growth Corporation: Canopy Growth is a major global cannabis producer with EU-GMP medical cannabis operations in Europe producing dried flower APIs. Broad incumbent comparable to GreenBe's pharmaceutical-grade cannabis API offering, though at significantly larger scale.
- Aurora Cannabis: Aurora Cannabis operates EU-GMP certified medical cannabis production in Europe and produces dried flower and cannabinoid APIs for pharmaceutical distribution. Direct comparable as a multi-country EU-GMP cannabis API producer targeting pharmaceutical clients.
- Jazz Pharmaceuticals (GW Pharmaceuticals): Jazz Pharmaceuticals owns GW Pharmaceuticals, the originator of cannabinoid-based medicines (e.g., Sativex, Epidiolex) and a major buyer of cannabis APIs in Europe. Comparable as a pharmaceutical-grade cannabinoid-medicine counterpart and potential customer.
- Tilray Brands: Tilray is one of the largest global cannabis cultivators with EU-GMP certified medicinal cannabis production in Portugal and Germany, supplying pharmaceutical-grade flower and extracts across Europe. Directly comparable as a competitor in EU-GMP cannabis APIs targeting the same pharmaceutical customer segment.
Emerging players
- Flora Growth Corp: Flora Growth operates cannabis cultivation and processing facilities in Colombia with EU-GMP ambitions targeting European pharmaceutical supply. Comparable as an emerging multi-country cannabis cultivator pursuing the EU pharmaceutical API opportunity.
Direct peers
- Cantourage Group: Cantourage is a Berlin-based medical cannabis distribution and processing platform that imports EU-GMP cannabis flower and supplies German pharmacies. Directly comparable as a Europe-focused B2B medical cannabis supplier serving pharmaceutical channels.
- Segra International: Segra International is a Canadian cannabis ag-tech and tissue-culture genetics company whose clones are now distributed in Europe through GreenBe. Comparable as a cannabis-genetics IP holder and tissue-culture operator partnering with GreenBe for European distribution.
- Khiron Life Sciences: Khiron is a vertically integrated medical cannabis company focused on European and Latin American markets, producing EU-GMP flower and extracts for pharmaceutical distribution. Comparable in target markets, regulatory positioning, and product breadth.
- Clever Leaves: Clever Leaves is a vertically integrated medical cannabis cultivator with EU-GMP certification operating in Colombia and Portugal, supplying pharmaceutical-grade flower to European markets. Highly comparable in cultivation model, regulatory positioning, and customer segment.
- OrganiGram Holdings: OrganiGram is a Canadian licensed producer of medical and recreational cannabis with EU-GMP certification supplying European pharmaceutical markets with dried flower APIs. Closely comparable business model and product offering to GreenBe.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
GreenBe Pharma social profiles
Digital presenceGreenBe Pharma compliance and trust
Trust signalCompliance3 records
GreenBe Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
GreenBe Pharma leadership team
Management profileNumber of profiles
Profiles3 records
GreenBe Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
GreenBe Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about GreenBe Pharma
What does GreenBe Pharma do?
GreenBe Pharma cultivates medicinal cannabis in a GACP-certified greenhouse in Elvas, Portugal, and processes it in an adjacent EU-GMP facility to produce Active Pharmaceutical Ingredients (dried cannabis flowers with tailored THC, CBD, and CBDV chemotypes) supplied to pharmaceutical companies. The company also offers GMP cultivation and processing services, planned extraction/purification capabilities, and chemotype research services for clinical trials and contractual research projects.
Is GreenBe Pharma a public or private company?
GreenBe Pharma is a private company. It is classified as family owned and is currently operating.
When was GreenBe Pharma founded?
GreenBe Pharma was founded in 2022. It employs 11 to 50 people.
Where is GreenBe Pharma based?
GreenBe Pharma is headquartered in Elvas, Portugal, in the Europe region.
How does GreenBe Pharma make money?
Four revenue lines are on record. Cannabis Flower Sales (EU-GMP) is the primary driver. The others are active Pharmaceutical Ingredients (API), research Services and extract and Purification.
Who are GreenBe Pharma's main competitors?
Broad incumbents on record are Canopy Growth Corporation, Aurora Cannabis, Jazz Pharmaceuticals (GW Pharmaceuticals) and Tilray Brands. Flora Growth Corp is listed as an emerging player. Direct peers are Cantourage Group, Segra International, Khiron Life Sciences, Clever Leaves and OrganiGram Holdings.
Does GreenBe Pharma have an API?
No public API is recorded for GreenBe Pharma.
What industry is GreenBe Pharma in?
GreenBe Pharma's product category is Medicinal Cannabis APIs / Pharmaceutical Ingredients. Its primary akta.pro industry code is AFAGAGAE, Medicinal Plant Farming (Botanical/Pharmaceutical Crops). Its NAICS code is 325411 and its SIC code is 2833.